Lv52
1590 积分 2021-11-16 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
39分钟前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
51分钟前
已完结
CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma
15天前
已关闭
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
15天前
已完结
Targeting cereblon in hematologic malignancies
19天前
已完结
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos
19天前
已完结
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
19天前
已完结
Targeting cereblon in hematologic malignancies
19天前
已完结
Cereblon-Targeting Ligase Degraders in Myeloma
19天前
已完结
皖公网安备34019202002308
